Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | EEF2K | O00418 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370027 | 0.92 | EPHX2 (0.37) | PTGDR2POLBS1PR3S1PR1CNR2 | |
| SCHEMBL369536 | 0.88 | POLB (0.38) | CYP2C9CYP2C19POLBS1PR3S1PR1 | |
| SCHEMBL368564 | 0.88 | GPBAR1 (0.34) | PTGDR2POLBS1PR3RORCS1PR1 | |
| SCHEMBL1389716 | 0.88 | GPBAR1 (0.34) | PTGDR2POLBS1PR3RORCS1PR1 | |
| SCHEMBL368566 | 0.88 | GPBAR1 (0.34) | PTGDR2POLBS1PR3RORCS1PR1 | |
| SCHEMBL1390467 | 0.88 | POLB (0.37) | CYP2C9CYP2C19POLBS1PR3S1PR1 | |
| SCHEMBL371366 | 0.87 | KMT2A (0.46) | CYP2C9CYP2C19POLBS1PR3S1PR1 | |
| SCHEMBL369928 | 0.86 | CYP2C9 (0.39) | CYP2C9CYP2C19POLBS1PR3S1PR1 | |
| SCHEMBL368299 | 0.84 | ADRA1D (0.36) | PTGDR2BRD4MDM2EEF2KGAA | |
| SCHEMBL369981 | 0.83 | EPHX2 (0.38) | CYP2C9CYP2C19S1PR3S1PR1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | PTGDR2 71/4885CYP2C9 1676/4885CYP2C19 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.